GSK plc (GSK)
GSK's Blenrep drug receives FDA approval, but faces scrutiny over label restrictions. The company is also actively pursuing strategic partnerships and acquisitions to bolster its pipeline.
About GSK plc
GSK plc is a multinational pharmaceutical and biotechnology company.
GSK plc uses the ticker $GSK for trading. Listed in the Stocks category within the Healthcare sectors.
Insights
- GSK plc (GSK) social dominance is up 477.97% from the previous week.
Price: $58.90
Price 24-Hour Time-Series Raw Data
The stock price is near a 52-week high, supported by positive news like the FDA approval of Blenrep and recent acquisitions. However, potential volatility exists due to Blenrep's label restrictions, which are a significant critical theme in social discussions.
24-Hour: 0.1% 7-Day: -2.04% 30-Day: 22.21%
1-Year High: $60.20 on 2026-02-06
1-Year Low: $33.60 on 2025-04-10
AltRank: [-----]
AltRank 24-Hour Time-Series Raw Data
GSK plc (GSK) is currently AltRank #1,237 based on combined combined social and market metrics
Daily Average: [---]
[--] Week: [-----] +310
[--] Month: [-----] +1,000
[--] Months: [-----] +817
[--] Year: [-----] +688
1-Year High: [-----] on 2026-01-31
1-Year Low: [--] on 2025-06-08
Galaxy Score: [-----]
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [--]
[--] Week: [--] [---]
[--] Month: [--] +13
[--] Months: [--] [---]
[--] Year: [--] [---]
1-Year High: [--] on 2025-05-13
1-Year Low: [--] on 2025-07-03
Engagements: [-----] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [------]
[--] Week: [-------] -46%
[--] Month: [-------] +152%
[--] Months: [---------] +2.10%
[--] Year: [---------] -1.40%
1-Year High: [-------] on 2025-07-30
1-Year Low: [---] on 2025-12-07
Engagements by network (24h): Reddit: [--] X: [-----] YouTube: [--]
Mentions: [---] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [---]
Daily Average: [---]
[--] Week: [---] -13%
[--] Month: [---] +57%
[--] Months: [-----] -28%
[--] Year: [-----] +55%
1-Year High: [---] on 2025-08-03
1-Year Low: [--] on 2025-12-07
Mentions by network (24h): Reddit: [--] X: [---] YouTube: [--]
Creators: [---] (24h)
Creators 24-Hour Time-Series Raw Data
[---] unique social accounts have posts mentioning GSK plc (GSK) in the last [--] hours which is down 10% from [---] in the previous [--] hours
Daily Average: [--]
[--] Week: [---] -9.60%
[--] Month: [---] +73%
[--] Months: [-----] -17%
[--] Year: [-----] +57%
1-Year High: [---] on 2025-06-28
1-Year Low: [--] on 2025-12-07
The most influential creators that mention GSK plc in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @BioStocks | [--] | [------] | [--] | [-----] |
| @doepke_michel | [--] | [-----] | [--] | [---] |
| @2kse8emv9xIk1J9 | [--] | [-----] | [--] | [--] |
| @Yam_Trades | [--] | [-----] | [--] | [--] |
| @SamFazeli8 | [--] | [-----] | [--] | [--] |
| @GSK | [--] | [-------] | [--] | [--] |
| @fwpharma | [--] | [------] | [--] | [--] |
| @VizFactTheDude | [--] | [--] | [--] | [--] |
| @kinatsofrim | [--] | [---] | [--] | [--] |
| @RedChip | [--] | [-----] | [--] | [--] |
Sentiment: 76%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 76%
Daily Average: 73%
[--] Week: 100% no change
[--] Month: 72% -1%
[--] Months: 72% +13%
[--] Year: 72% -4%
1-Year High: 100% on 2025-03-21
1-Year Low: 37% on 2025-12-02
Most Supportive Themes:
- FDA Approval of Blenrep: (30%) GSK's multiple myeloma drug Blenrep has received FDA approval for specific patient groups, marking a significant regulatory milestone.
- Partnerships and Acquisitions: (20%) GSK is actively engaging in strategic partnerships and acquisitions, such as the deal with Empirico, to expand its pipeline and market reach.
Most Critical Themes:
- Blenrep Label Restrictions: (40%) Despite FDA approval, Blenrep's label is narrower than anticipated, raising concerns about its near-term commercial upside and market penetration.
- Pipeline Development Challenges: (35%) GSK faces ongoing challenges in its R&D pipeline, with some drug candidates like the one partnered with Alector failing in late-stage trials.
Social Dominance: 0.011%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.011%
Daily Average: 0.02%
[--] Week: 0.034% +0.028%
[--] Month: 0.011% -0.00517%
[--] Months: 0.011% -0.00467%
[--] Year: 0.011% -0.00437%
1-Year High: 0.067% on 2025-08-03
1-Year Low: 0.0024% on 2025-12-07
Market Dominance: 0.134%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: 0.134%
Daily Average: 0%
1-Year High: 2.90% on 2025-03-31
1-Year Low: 0.095% on 2025-07-21
Market Cap: $118,251,422,371
Market Cap 24-Hour Time-Series Raw Data
Current Value: $118,251,422,371
Daily Average: $85,744,885,104
[--] Week: $119,074,145,656 +0.75%
[--] Month: $118,251,422,371 +22%
[--] Months: $118,251,422,371 +47%
[--] Year: $118,251,422,371 +60%
1-Year High: $120,860,057,176 on 2026-02-06
1-Year Low: $68,072,746,997 on 2025-04-10
Top GSK plc Social Posts
Top posts by engagements in the last [--] hours
Showing a maximum of [--] top social posts without a LunarCrush subscription.
"$azn $pfe $jnj $nvs $bmy $gsk $abbv $mrk $sny #biotech #pharma #cancer $nvo $lly $xbi $amgn $rhhby $aapl $tsla $abvx $rvmd $sgmo 1/🚨 This short and excellent FT article tells the tale of AstraZenecas huge success story and how $AZN is paving its way towards fulfilling its ambitious corporate goal of $80B in revenue by [----]. This massive achievement is based mainly on a fantastic track record of [--] https://t.co/WfYnmDHjTV 1/🚨 This short and excellent FT article tells the tale of AstraZenecas huge success story and how $AZN is paving its way towards fulfilling its ambitious corporate goal of"
X Link @HalevyMike 2026-02-16T15:56Z [----] followers, [---] engagements
"4/The fact that AstraZenecas internal growth is unrelated to the obesity and weight loss frenzy - unlike $LLY and $NVO GLP-1 drugs makes $AZN success even more remarkable. To truly understand how big AstraZenecas success story really is - for comparison analysts expect British peer $GSK revenue to rise from $40B in [----] to only $51B by the end of the decade - which is much lower than $AZN. Interestingly enough analysts not only predict that AstraZeneca will reach its $80B goal but many even predict that the company will slightly exceed its target"
X Link @yaireinhorn 2026-02-16T15:21Z 18.5K followers, [---] engagements
"SHINGRIX1 $GSK I am at and wanted you to know. Check out the details or leave a comment at: https://t.co/SThKkxYoBY I am at and wanted you to know. Check out the details or leave a comment at: https://t.co/SThKkxYoBY"
X Link @onotakashi 2026-02-16T02:03Z 12.7K followers, [----] engagements
"Drst olmak gerekirse $MU Micron ve $TSM Taiwan Sem. bu listede grmek tuhafma gitti. 😳 [--] MOST UNDERVALUED STOCKS WITH 20%+ ROIC & RULE OF [--] 40% [--]. $MSFT Microsoft [--]. $TSM Taiwan Semi [--]. $MU Micron [--]. $NVO Novo Nordisk [--]. $SAN Banco Santander [--]. $GSK GSK [--]. $MO Altria [--]. $ADBE Adobe [--]. $COIN Coinbase https://t.co/Jtj17TzyZE [--] MOST UNDERVALUED STOCKS WITH 20%+ ROIC & RULE OF [--] 40% [--]. $MSFT Microsoft [--]. $TSM Taiwan Semi [--]. $MU Micron [--]. $NVO Novo Nordisk [--]. $SAN Banco Santander [--]. $GSK GSK [--]. $MO Altria [--]. $ADBE Adobe [--]. $COIN Coinbase https://t.co/Jtj17TzyZE"
X Link @ProfKayaFinance 2026-02-15T15:23Z 20K followers, [----] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing